Infofin | ULB

Liste des projets

Recherche de projets

Agenda

S'enregistrer

Connexion

Description de l’appel

Programme :

TRANSCAN 3 - ''Joint Call (JTC 2023) Call for research proposals: “Translational research on cancer epigenetics”''

Organisation :

F.R.S.-FNRS

Deadline :

21/07/2023 - Pre-proposal

Deadline2 :

15/12/2023 - Full-proposal

Type d'information :

Financement

Type de programme :

Appels à projets de collaboration internationale

Description courte :

TRANSCAN-3 launches its third Joint Transnational Call for research proposals (JTC 2023) on the following topic:

“Translational research on cancer epigenetics”

The expected outcome of the call is to improve the efficacy of current detection, diagnosis, prognosis and treatment of cancers, through the development of novel approaches based on a better understanding of cancer epigenetics.

Description complète :

Aims of the call:

The expected outcome of the call is to improve the efficacy of current detection, diagnosis, prognosis and treatment of cancers, through the development of novel approaches based on a better understanding of cancer epigenetics. The specific objectives of this funding opportunity are to stimulate new partnerships between researchers and clinicians and support original, high-quality projects, with significant clinical impact.
In the context of translational research, this topic will comprise two general aims, each with several aims, which concur to the possible clinical applications. Proposals should cover one or several of the specific aims listed below and should be built from a sound hypothesis. Particular attention should be given to gender balance inclusion in order to intercept sex/gender differences and to consider the role of these differences in the addressed questions.

Aim 1) The role of epigenetics in cancer initiation and progression
Specific aim 1.1: To understand cancer initiation and progression by characterisation of the epigenetic landscape.
Specific aim 1.2: To define epigenetic features of cells in the tumour microenvironment that may promote tumour progression (e.g., immune cells, vascular cells, microbiota).
Specific aim 1.3: To study the role of epigenetic modifications as predictors of cell persistence or treatment resistance.
Specific aim 1.4: To validate epigenetic markers useful to improve early detection and diagnosis by exploring the correlation between epigenetics and clinical cancer manifestation.

Aim 2) Validation of new epigenetics-based therapeutic strategies to limit cancer progression, prevent relapse/recurrence or increase the efficiency or reduce toxicity of existing anti-cancer therapies.
Specific aim 2.1: To validate novel therapeutic targets (novel targets should be evaluated in translational studies with regard to their impact on treatment efficacy, safety and patient reported outcomes).
Specific aim 2.2: To study the potential use of epigenetic modulators to overcome resistance to anti-cancer therapies.
Specific aim 2.3: To develop novel epidrugs/therapeutic approaches, through phase I and II clinical trials (investigating combinations of available treatments, new therapeutics, new administration schemes, etc.) to improve safety and efficacy of treatments (objective responses; patient reported outcomes regarding morbidity and quality of life; …).
Specific aim 2.4: To develop novel theranostic approaches involving epigenetics of cancer. Approaches combining diagnostic (imaging technics) and targeted treatment to detect cancer cells and assess treatment efficacy (radionuclide, radiopharmaceuticals, nanoparticles, nanomaterial, …).

The following types of research projects are excluded from the call:
Analysis of preclinical models limited to cell lines and animal models;
Phase III and IV clinical trials;
Studies not compliant with the COMMISSION REGULATION (EC) No 800/2008 (http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:214:0003:0047:en:PDF), with specific reference to the articles 30, 31, 32, and 33. For full reference, please see also the COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS dated 20.12.2011 (http://ec.europa.eu/services_general_interest/docs/comm_quality_framework_en.pdf);
Studies not compliant with the Commission Regulation (EU) No 651/2014 of 17 June 2014 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L:2014:187:FULL&from=EN.

Critères d’admission/attribution :

Eligibility rules for the consortia:

Only transnational projects will be funded.
Applications will be submitted by the coordinator. The coordinator and each of the individual project partners (representing research groups) will be funded by the funding organisation from their country/region that is participating in the TRANSCAN-3 JTC 2023, and are therefore subject to national/regional eligibility rules.

Each research consortium must involve a minimum of three (3) and a maximum of six (6) partners (comprising the project coordinator) eligible for funding, coming from different countries whose funders participate in the call.

The partners must be from at least three (3) different countries participating in the call. In addition, a consortium must not involve more than two (2) research groups from the same country (in such cases the minimum number of groups must be four (4), coming from three (3) different countries).

Each consortium must involve at least one basic or pre-clinical research team and one clinical team. It is also recommended to include an expert team in methodology, biostatistics or bioinformatics, depending on the type of work planned.

Eligibility for belgian partners (F.R.S. - FNRS)

Applicants requesting funding from F.R.S. FNRS must comply with the following rules.
The applicant must be affiliated to a university from the Wallonia-Brussels Federation (FWB).
At the closure of the call, the applicant should also:
- Be a permanent researcher of F.R.S-FNRS (Chercheur qualifié, maître de recherches ou Directeur de recherche) or;
- Hold a tenure track position (or an assimilated position including pending tenure track) with a research institution from the FWB
After the submission of applications, the F.R.S.-FNRS and the research institutions are required to verify the eligibility of the candidates. The F.R.S.-FNRS reserves the right to refuse those whose eligibility criteria would not comply with the Regulation. In order the check the compliance with these eligibility criteria, please contact your contact person at ULB-TTO (see details below). The complete F.R.S-FNRS rules for international research projects is available at the following link: https://www.frs-fnrs.be/docs/Reglement-et-documents/International/FRS-FNRS_PINT-Multi.pdf

Financement :

Each partner is funded separately by the national/regional funding organisation they are applying to. They must fulfil the conditions of their funding organisation.
The maximum amount of requested funding per project is 200.000 EUR for a total period of thee years. If the project involves the recruitment of a PhD student, the project duration of the F.R.S.-FNRS sub-project could be up to four years.

Eligible costs items

Personnel costs: 50,000€ EUR per year on average for the duration of the project. The usual duration of ERA-NET research programmes is three years. However, when the project involves a PhD student, the principal investigator can apply for an additional one year funding in order to complete the four years PhD programme. Since this programme is NOT co-funded by the European Commission, this final year should be included in the budget submitted to this call.

Equipment: can be eligible up to 20% of the total budget of the project

Running costs: travel expenses; organisation of small scientific events in Belgium; consumables and the following support costs: consumables Publication Designing (conception d’ouvrage) Dictionary Production (réalisation de dictionnaire) Purchase of Books Encoding Software Access Rights Congress Registration Fees Purchase of Computer Scanning Travel costs Visa costs Open Access publication of an article up until 500 euros (see F.R.S-FNRS Open Access policy).

“Overhead” is not an eligible cost for FNRS. If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS.

Pour postuler / aide du Département Recherche :

TRANSCAN-3 JTC 2023 will be implemented through a two-stage submission procedure: pre-proposals and full proposals. Both pre- and full proposals must be written in English and submitted to the JCS by the coordinator through the PT-Outline Electronic Submission System exclusively.

Applicants must provide basic administrative data by submitting an administrative application on e-space within 5 working days after the general deadline of the call to be eligible. Please select the “PINT-MULTI” funding instrument when creating the administrative application. This call follows a one-step procedure.

Deadlines:
- Pre-proposal: 21 July 2023 at 12:00 (CEST)
- FNRS administrative form: 28 July 2023 at 14:00 (CEST)
- Full proposal: 15 December 2023 at 12:00 (CET)

Contact interne ULB :

Nemeghaire Stéphanie

+32478630969

stephanie.nemeghaire@ulb.be

Contact externe :

Agnès ROBA

+3225049236

international@frs-fnrs.be

Vous souhaitez recevoir de l’information destinée à quel type de profil :

Chercheurs

Discipline(s) scientifique(s) de l’appel :

Santé publique, Sciences biomédicales

Documents :

Nom	Fichier
call text	TRANSCAN_3_Call_text__JTC2023_.pdf
guidelines for applicants	TRANSCAN_3_Guidelines_for_appl.pdf
pre-proposal form	TRANSCAN_3_Pre_proposal_applic.docx

Télécharger tous les documents

Une question sur une fiche Infofin ? Contactez le contact interne ULB en charge du programme et/ou le contact externe lié à l'organisme en question.